Drug Safety Evaluation Using Real World Adverse Event Patterns
Abstract
The study involves pharmacovigilance databases, electronic health records, and published trial evidence to determine infrequent toxicity pattern, confirm organ-specific patterns of injury and detect responses of delayed onset. Mechanical plausibility was achieved with the testing of drug interactions signaling with systematic biochemical laboratory signals, including ALT, creatinine, troponin, and INR. The isolation of regional clusters of adverse events was achieved through reporting networks such as FAERS, VigiBase, EudraVigilance, and they determine genetic predispositions and sociocultural risk factors. In a variety of populations, comparative cohort designs separated true safety signals and spurious associations to improve causal inferences. The outcome demonstrates the relevance of the comorbidity profiling, longitudinal monitoring of exposure and geospatial mapping in identifying high-risk groups of patients. Altogether, the present work demonstrates that the multidimensional secondary strategies may be employed to develop the robust evidence-based regulatory recommendations, clinical decision-making and therapy-specific strategies to improve global pharmacovigilance and patient safety outcomes.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing
- Laboratory-based nationwide surveillance of antimicrobial resistance in Ghana
- Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains
- Incidence and factors associated with development of phlebitis: results of a pilot study cohort
- Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori
- Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.